Olatec Therapeutics, Inc. ("Olatec"), developing one of the most clinically advanced specific oral NLRP3 inhibitors, dapansutrile, today announced that two patients have been randomized in a 12-month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results